Journal article Open Access


Dr. K. Ramesh1*, Dr.M.Ganesh2, Dr. Suresh Kumar Packiriswamy3, G.Sridhar4

MARC21 XML Export

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="">
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Osimertinib Mesylate, Particle Size, Disintegrant, Dissolution Profile.</subfield>
  <controlfield tag="005">20200120171938.0</controlfield>
  <controlfield tag="001">2621043</controlfield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">932258</subfield>
    <subfield code="z">md5:b79731050c29cddd848ffead13758864</subfield>
    <subfield code="u"></subfield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2019-04-02</subfield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">openaire</subfield>
    <subfield code="p">user-iajpr</subfield>
    <subfield code="o"></subfield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="u">1Nova College of Pharmacy, Vegavaram, Jangareddygudem Mandal, West Godavari Dist, A P, India. 2St.Mary's College of Education, Sarpavaram, Kakinada, Andhra Pradesh, India. 3Nova College of Pharmacy, Vegavaram, Jangareddygudem Mandal, West Godavari Dist, Andhra Pradesh, India. 4Research Associate, Hetero Labs Ltd, Jeedimetla, Hyderabad.</subfield>
    <subfield code="a">Dr. K. Ramesh1*, Dr.M.Ganesh2, Dr. Suresh Kumar Packiriswamy3, G.Sridhar4</subfield>
  <datafield tag="245" ind1=" " ind2=" ">
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-iajpr</subfield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u"></subfield>
    <subfield code="a">Creative Commons Attribution 4.0 International</subfield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2"></subfield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">&lt;p&gt;Osimertinib mesylate is a kinase inhibitor, prescribed for the treatment of patients, who are diagnosed with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC). The Innovator of the product is AstraZeneca and its brand name in US and EU market is TAGRISSO&amp;reg; (Osimertinib) 40 mg and 80 mg film coated Tablets. The recommended dose is one 80 mg tablet once daily taken orally with or without a meal. Approximately, 80-90 % of lung cancer comprise NSCLC. Solubility of Osimertinib is known to be affected by pH, it belongs to BCS class-III molecule. The current work attempted to study the impact of both particle size of API and concentrations of disintegrant (L-HPC) on in vitro drug release profiles of Osimertinib from tablet dosage form in comparison to in vitro drug release profiles of corresponding Innovator product in US market. Based on the scientific discussion of TAGRISSO&amp;reg; in EU market, and to increase the flow properties of blend for compression into tablets, dry granulation method (by Roller compaction) was adopted. Assay and in vitro dissolution of the finished product was analysed by UV method. The obtained dissolution results suggested that 500 ml of pH 4.5 Acetate buffer at 25 rpm was found to be more discriminatory media than pH 6.8 Phosphate buffer and pH 1.3 (containing 0.2 % NaCl) and film coated tablets with input micronized API (&amp;lt;10&amp;mu;) has shown similar physical characteristics (hardness, disintegration time) and in vitro drug release profiles to that of Innovator product.&lt;/p&gt;</subfield>
  <datafield tag="773" ind1=" " ind2=" ">
    <subfield code="n">doi</subfield>
    <subfield code="i">isVersionOf</subfield>
    <subfield code="a">10.5281/zenodo.2621042</subfield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.5281/zenodo.2621043</subfield>
    <subfield code="2">doi</subfield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
All versions This version
Views 187188
Downloads 187187
Data volume 174.3 MB174.3 MB
Unique views 178179
Unique downloads 173173


Cite as